Skip to main content

Ascendis Pharma A/S 6-K, filed Nov 12, 2026

Ascendis Pharma A/S (ASND)

6-K 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 6-K

Ascendis Pharma A/S filed this 6-K on November 12, 2026.

Ascendis Pharma A/S received FDA approval for YUVIWEL in February 2026 and sold its priority review voucher for $187.5 million, generating €158.1 million in income. It also settled litigation with BioMarin over YUVIWEL and navepegritide. AI summary